RBC begins Sunesis at sector perform

RBC Capital Markets analyst Jason Kantor started coverage of Sunesis Pharmaceuticals, Inc. with a sector perform, speculative risk, rating. The company's in-licensed cancer drug candidates have shown promising signs of efficacy in early studies, while ongoing phase 2 and phase 1/2 clinical trials could provide significant proof of concept, according to Kantor. Shares of the South San Francisco, Calif.-based clinical stage biopharmaceutical company were unchanged at $4.90. (Nasdaq: SNSS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.